Accelerated Corneal Crosslinking Procedure Receives CE Approval

A procedure designed to strengthen the cornea after LASIK called LASIK Xtra, has received CE approval for marketing in Europe and was just approved in Canada as well.

Marketed by Avedro, Inc., Lasik Xtra is an accelerated corneal crosslinking procedure that applies Avedro’s VibeX riboflavin ophthalmic solution to the cornea, and then uses it’s KXL System to irradiate the cornea with UV-A rays that only takes two minutes to apply, making it a good solution to combine with LASIK. Avedro said their studies show the procedure has helped people who received hyperopic LASIK, which tends to regress more than myopic LASIK, and will help patients maintain their vision correction they received from LASIK.

Although corneal crosslinking has not received FDA approval yet, Avedro’s VibeX solution has received orphan drug approvals from the agency. Orphan drug status is usually conferred on treatments for rare medical conditions, in this case, keratoconus, which is a gradual thinning of the cornea.


For more information on the latest ophthalmic equipment to help your practice expand contact us at and let one of our industry experts help.